Biocause Pharma(SZ:000627)2025-01-20 12:10Financial Performance Expectations - The company expects a net profit loss for 2024, estimated between -50,000.00 million and -75,000.00 million CNY, compared to a loss of 65,175.85 million CNY in the previous year[3]. - The projected revenue for 2024 is between 4,000,000.00 million and 4,300,000.00 million CNY, down from 4,969,887.37 million CNY in the previous year, indicating a decline[3]. - The basic earnings per share are expected to be between -0.10 CNY and -0.15 CNY, compared to -0.13 CNY in the previous year[3]. Factors Influencing Financial Results - The increase in loss is attributed to the downward trend in the 750-day moving average of government bond yields, leading to higher reserve provisions by the subsidiary Guohua Life Insurance[5]. Business Operations and Strategy - Guohua Life Insurance achieved original insurance premium income of 34.639 billion CNY in 2024, maintaining stable premium income while optimizing product structure[6]. - The company is focused on optimizing business structure and asset allocation, while enhancing new technology applications and talent reserves to improve operational capabilities[6]. Reporting and Disclosure - The financial data presented is preliminary and has not been audited by the accounting firm[4]. - The company will provide detailed disclosures regarding the 2024 operating performance in the annual report[7]. - Investors are advised to invest rationally and be aware of risks associated with the company's performance[7]. - The company’s designated information disclosure media include China Securities Journal, Securities Times, Shanghai Securities Journal, and the CNINFO website[7].